2-(Ethoxycarbonyl)-1-benzothiophene-4-boronic acid, 97%, 1g

(6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(thiophen-2-yl)acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 95.0%, 5g

N-(8-Amino-6-fluoro-5-methyl-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide, 97%, 25g

5-CHLORO-7-IODO-1H-PYRAZOLO[3,4-C]PYRIDINE, 95%, 100mg

4-Amino-2-chloro-5-methylpyrimidine, 95.0%, 25g

Kentanserin, 95%, 1g

1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone, 95.0%, 50g

N,N-Dimethylazetidine-3-carboxamide hydrochloride, 95.0%, 100mg

Long working distance plan 4x/0.13 IOS objective, corrected for 1 mm thickness

2-(2-(Difluoromethoxy)phenyl)-2-hydroxyacetic acid, 98%, 500mg

2-Acetoxy-2',4'-methoxybenzophenone, 90.0%, 1g

Methyl 4-mercaptobenzoate, 97%, 250mg

Methyl 5-bromo-2,3-difluorobenzoate, 95.0%, 1g